Sophia Genetics, a Lausanne, Switzerland-based data-driven medicine company, closed a $30m Series D funding round.
The round was led by Balderton Capital with participation from 360 Capital Partners and existing investors Invoke Capital and Alychlo.
The company intends to use the funds to further develop its technology, continue recruiting talent and accelerate hospitals’ adoption of clinical genomics testing, no matter if they are equipped (with a Next-Generation DNA Sequencing lab) or not.
The company’s dedicated team who develops SOPHiA is driven to support clinicians by providing them with the best diagnosis technologies and helping them to find treatment options that save lives.
Led by Dr. Jurgi Camblong, CEO and Co-Founder, Sophia is a health tech company which has developed SOPHiA AI, an advanced technology hich accurately analyzes and detects all types of genomic variants to help clinicians better diagnose and treat their patients. The company’s SOPHiA DDM® analytical platform is used by a global network of 334 institutions from 53 countries, testing over 125,000 patients to date.